These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 31056696)
1. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696 [TBL] [Abstract][Full Text] [Related]
2. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807 [TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095 [TBL] [Abstract][Full Text] [Related]
4. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094 [TBL] [Abstract][Full Text] [Related]
5. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Tamaki N; Kurosaki M; Yasui Y; Mori N; Tsuji K; Hasebe C; Joko K; Akahane T; Furuta K; Kobashi H; Kimura H; Yagisawa H; Marusawa H; Kondo M; Kojima Y; Yoshida H; Uchida Y; Loomba R; Izumi N Clin Infect Dis; 2021 Nov; 73(9):e3349-e3354. PubMed ID: 33544129 [TBL] [Abstract][Full Text] [Related]
6. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087 [TBL] [Abstract][Full Text] [Related]
7. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762 [TBL] [Abstract][Full Text] [Related]
8. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
9. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Chun HS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee CH; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Lee JH; Kim SU Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):378-385. PubMed ID: 32011388 [TBL] [Abstract][Full Text] [Related]
10. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861 [TBL] [Abstract][Full Text] [Related]
11. Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients. Liu YC; Cheng YT; Chen YC; Hsieh YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS Dig Dis Sci; 2023 Jan; 68(1):323-332. PubMed ID: 35895234 [TBL] [Abstract][Full Text] [Related]
12. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684 [TBL] [Abstract][Full Text] [Related]
14. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824 [TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004 [TBL] [Abstract][Full Text] [Related]
17. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Na SK; Song BC Clin Mol Hepatol; 2019 Sep; 25(3):234-244. PubMed ID: 30661334 [TBL] [Abstract][Full Text] [Related]
18. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma. Toyoda H; Tada T; Uojima H; Nozaki A; Chuma M; Takaguchi K; Hiraoka A; Abe H; Itobayashi E; Matsuura K; Atsukawa M; Watanabe T; Shimada N; Nakamuta M; Kojima M; Tsuji K; Mikami S; Ishikawa T; Yasuda S; Tsutsui A; Arai T; Kumada T; Tanaka Y; Tanaka J; Chayama K J Gastroenterol Hepatol; 2024 May; 39(5):949-954. PubMed ID: 38291715 [TBL] [Abstract][Full Text] [Related]
19. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]